Spark Therapeutics, Inc. (ONCE): Price and Financial Metrics
ONCE Stock Summary
- ONCE's price/sales ratio is 72.72; that's higher than the P/S ratio of 97.76% of US stocks.
- With a year-over-year growth in debt of 5,437.79%, NA's debt growth rate surpasses 98.96% of about US stocks.
- Over the past twelve months, ONCE has reported earnings growth of 151.53%, putting it ahead of 92.2% of US stocks in our set.
- If you're looking for stocks that are quantitatively similar to NA, a group of peers worth examining would be PTCT, ONVO, SPPI, OCUL, and SRPT.
ONCE Stock Price Chart More Charts
ONCE Price/Volume Stats
|Current price||$110.05||52-week high||$114.20|
|Prev. close||$113.57||52-week low||$34.53|
|Day high||$110.05||Avg. volume||891,560|
|50-day MA||$108.06||Dividend yield||N/A|
|200-day MA||$105.71||Market Cap||4.24B|
Spark Therapeutics, Inc. (ONCE) Company Bio
Spark Therapeutics is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.